Skip to main content

White paper

Clinicogenomics: Linked data advances research

Since the human genome was first sequenced life sciences researchers have sought to use this information to improve health. But they soon discovered that DNA sequence data alone has limited value when trying to understand the effects of genetic variation on health.

Today, researchers are increasingly linking genomic data to rich, longitudinal clinical information — a practice that yields clinicogenomics data. The field of clinicogenomics is unlocking novel insights to better understand diseases and to guide drug discovery, development and commercialization.

The study of clinicogenomics across large, diverse populations can help researchers:

  • Better understand disease pathways
  • Discover novel therapeutic targets
  • Identify variation in disease onset and progression
  • Evaluate drug safety and efficacy

Our latest white paper details the foundations of genomics-driven research and the sources of clinicogenomics data. It also highlights the ways clinicogenomics data can enhance clinical trials and fuel discovery and development of safer, more effective drugs.

Related healthcare insights

Article

4 ways small biopharma can harness RWD

Small and emerging biopharma companies are already having an impact on the industry. Learn how RWD can enhance the ability to innovate.

Article

Reassessing the Inflation Reduction Act with real-world evidence

Cut through the noise of the Inflation Reduction Act of 2022 with key points aimed to help life sciences leaders leverage impactful data.

Article

Catalyze the use of RWE in life sciences

Discover how using real-world evidence (RWE) in the life sciences industry can help catapult learning and drive impact for your company.